Correction of Lipid Metabolism Disorders in Diabetes Mellitus with Peptide Drugs.
Elagina. A A AA; Lyashev. Yu D YD; Lyashev. A Yu AY; Pronyaeva. T V TV; Chahine. A R AR
Key Findings
- Semax reduced total cholesterol, triglycerides, LDL and the atherogenic index, and increased HDL in diabetic rats.
- Deltalicin showed a stronger lipid‑lowering effect than Semax and the comparator drug sulodexide.
- The study used a streptozotocin‑induced diabetes model, with doses of 200 µg/kg for Semax and 100 µg/kg for deltalicin.
Practical Outcomes
- For biohackers, the data suggest Semax might have modest benefits for blood‑lipid control in a diabetic context, but the evidence is limited to animal models and the dosing is not directly translatable to humans. Until human trials are available, it’s not a reliable protocol for lipid management, though it may warrant monitoring as more research emerges.
Summary
In a rat study, the peptide Semax (200 µg/kg) and another peptide called deltalicin helped fix abnormal blood fats caused by diabetes. Both lowered total cholesterol, triglycerides, LDL and a heart‑risk index, while raising good HDL. Deltalicin worked a bit better than Semax, but the results are from animals, not people.
Abstract
We studied the effect of peptide drugs deltalicin and Semax on lipid metabolism disturbances in diabetes mellitus. Diabetes mellitus was modeled by single injection of streptozotocin (45 mg/kg) and rats with blood glucose ≥12 mmol/liter were selected for the further experiments. Deltalicin in a dose 100 μg/kg and Semax in a dose 200 μg/kg as well as sulodexide corrected lipid metabolism disorders: the content of total cholesterol, triglycerides, LDL, index of atherogenicity decreased and HDL concentration increased. Deltalicin produced more potent effect on lipid metabolism in rats with diabetes mellitus than sulodexide and Semax, which manifested in a significant decrease in total cholesterol and LDL concentration and index of atherogenicity.
Study Information
pubmed
2020
2020-04-04T00:00:00.000Z
10.1007/s10517-020-04764-2
3
15